Apogee Therapeutics, Inc.
APGE · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $167,865 | $68,424 | $27,786 |
| G&A Expenses | $49,005 | $24,579 | $2,941 |
| SG&A Expenses | $49,005 | $24,579 | $2,941 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $216,870 | $93,003 | $30,727 |
| Operating Income | -$216,870 | -$93,003 | -$30,727 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $34,742 | $9,018 | -$9,058 |
| Pre-Tax Income | -$182,128 | -$83,985 | -$39,785 |
| Tax Expense | $18 | $0 | $0 |
| Net Income | -$182,146 | -$83,985 | -$39,785 |
| % Margin | – | – | – |
| EPS | -3.3 | -1.66 | -0.79 |
| % Growth | -98.8% | -110.1% | – |
| EPS Diluted | -3.3 | -1.66 | -0.79 |
| Weighted Avg Shares Out | 55,194 | 50,656 | 50,674 |
| Weighted Avg Shares Out Dil | 55,194 | 50,656 | 50,674 |
| Supplemental Information | – | – | – |
| Interest Income | $34,742 | $9,018 | $92 |
| Interest Expense | $0 | $0 | $9,150 |
| Depreciation & Amortization | $189 | $9,018 | $0 |
| EBITDA | -$216,681 | -$74,967 | -$39,785 |
| % Margin | – | – | – |